ClinicalTrials.gg
RecruitingNCT05428137KOBIUpdated Mar 5, 2024

Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals

An interventional study of Probiotic and Postbiotic in Obesity and Abdominal Obesity, sponsored by The Archer-Daniels-Midland Company. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Primary conditionObesity, AbdominalRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Abdominal
Why
  1. The study's listed conditions name Obesity, Abdominal, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Archer-Daniels-Midland Company · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

Investigate the effect of a probiotic (live bacteria) and postbiotic (heat-treated bacteria) strains in overweight individuals.

Read the detailed description

This study aims to investigate the safety and efficacy of live and heat treated bacteria on body composition of overweight individuals. The trial will be run in a single research centre and will recruit adult men and women, with BMI of 25-33kg/m2 with abdominal obesity.

02

Conditions studied

  • Obesity
  • Abdominal Obesity

Browse trials for

03

In context

Obesity, Abdominal Reclassified

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

This study's planned enrollment of 180 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.

Browse Obesity, Abdominal studies →

Lead sponsor

The Archer-Daniels-Midland Company is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Compared within Obesity, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 25-33kg/m2
  • Abdominal obesity (female waist circumference>85cm; male waist circumference>90cm)
  • written

Exclusion criteria

Exclusion Criteria:

  • Taking the following medication within 1 month before starting the study: appetite stimulants/suppressants, lipid lowering drug,
  • taking antibiotics within 2 months before starting the study
  • secondary obesity or secondary hypertension, diabetes type 1, GI disease, dyslipidaemia, type 2diabetes, hypertension
  • consumption of pre- and probiotic-enriched products or dietary supplement for at least 4 weeks prior to the first screening visit
  • nicotine, drug or alcohol abuse,
  • other condition that, in the opinion of the investigators, would make participation not in the best interest of the patient or could prevent, limit or confound the Study's results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Probiotic

    Live bacteria strain in a form of a capsule daily for 16 weeks

    Dietary Supplement: Probiotic

  • Active comparator
    Postbiotic

    Heat treated bacteria strain in a form of a capsule daily for 16 weeks

    Dietary Supplement: Postbiotic

  • Placebo comparator
    Placebo

    Placebo in a form of a capsule administered for 16 weeks

    Other: Placebo

Interventions

  • Dietary supplementProbiotic

    Live bacteria strain in a form of a capsule daily for 16 weeks

  • Dietary supplementPostbiotic

    Heat treated bacteria strain in a form of a capsule daily for 16 weeks

  • OtherPlacebo

    Placebo in a form of a capsule given for 16 weeks

06

What researchers measure

Primary outcomes

  1. Change in visceral fat area

    Difference in visceral fat area (cm\^2) measured using CT from week 0 to week 16

    Time frame: From week 0 to Week 16

Secondary outcomes

  1. Change in body weight

    Body weight (kg) will be assessed at week 0, Week 12, Week 16

    Time frame: Week 0, Week 12, Week 16

  2. Change in waist circumference

    Change in waist circumference (cm) at week 0, week 12 and week 16

    Time frame: Week 0, Week 12, Week 16

  3. Change in body fat composition

    Change in body fat composition using dual-energy x-ray absorptiometry (DEXA) at week 0, Week 12, Week 16

    Time frame: Week 0, Week 12, Week 16

  4. Change in peripheral blood cholesterol

    Change in Cholesterol concentration (mg/dL) (total, HDL, LDL) in peripheral blood from week 0 to week 16

    Time frame: Week 0, Week 16

  5. Change in serum insulin concentration

    Change in serum insulin from week 0 to week 16

    Time frame: Week 0, Week 16

  6. Change in peripheral blood glucose

    Change in blood glucose from week 0 to week 16

    Time frame: Week 0, Week 16

  7. Change in plasma leptin levels

    Change in leptin week 0 to week 16

    Time frame: Week 0, Week 16

  8. Dietary survey

    Food cravings will be assessed using the Food Craving Questionnaires (FCQ) at week 0 and week 16. The change in score compared to baseline and between groups will be assessed at the end of the study.

    Time frame: Week 0, Week 16

  9. Microbiome analysis

    Stool samples will be collected from participants to analyse change in intestinal microbiota community composition by 16SRNA sequencing

    Time frame: Week 0, Week 16

  10. Mood questionnaire

    Participants mood will be assessed using the PHQ-9 (Patient Health Questionnaire-9). The change in score compared to baseline and between groups will be assessed at the end of the study.

    Time frame: Week 0, Week 16

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Korea St. Vincent's Hospital
    Seoul, Korea, Republic of
    Recruiting
    • MI KYUNG KIM, Dr · Contact
    • Song Sang-wook, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 29 months after the start.

Of 117 interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
Jun 22, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05428137
Lead sponsor
The Archer-Daniels-Midland Company
Responsible party
Sponsor
First posted
Jun 22, 2022
Start date
Jul 1, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 5, 2024

Study contacts

Vineetha Vijayakumar, PhD
Contact
vineetha.vijayakumar@adm.com
07885966211
Daniel Ramon Vidal
study chair · ADM Biopolis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion